Brief report · 28 Jan 2025
Short communicationPublished 31 Jan 2022
A Review of Commercialisation Issues for Biosensors and Bioelectronics
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
While conventional technologies such as quantitative real-time polymerase chain reaction (PCR) are used to detect COVID-19, they are time-consuming, labour-intensive and are sparsely unavailable in remote settings. Point-of-care (POC) paper-based biosensors, such as lateral flow test strips or microfluidic biosensors are typically low-cost and user-friendly, are now being used for rapid diagnosis but since they are indicators do not always produce accurate results. These sensitive specific biosensors are used to detect antibodies, antigens or nucleic acids in samples of saliva, sputum and blood. Biosensors can be applied for medical diagnosis of many other diseases, environmental monitoring, food, water, and agricultural product processing. They can be connected to smartphones and tablets to provide a quick personalised result to uses that save time and enables clinicians to spend it on seriously infected patients. As expected, there are now numerous papers, research reports, public and private surveys, videos etc, being published and carried out worldwide on biosensor-based diagnostic systems for Covid and other virus diseases that can be seen on the Internet. This presentation is therefore confined to reviewing some of the key manufacturing, commercialisation, marketing and supply issues associated with making specific biosensor systems widely available to a global population including less technologically developed countries. The global biosensors market size is forecast from 2020 to 2025, with a CAGR of 9.6%% is expected to reach USD 31270 million, with applications in healthcare, and the environment. Advances in the last decade in bioelectronic systems, artificial intelligence, nanotechnology and genetic engineering have produced an exponential surge in the development, manufacture and performance of specific biosensors and biosensor systems. The recent pandemic has also made a significant contribution to these advancements and emphasised the need to improve the supply and delivery of such systems to the global market.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.
More from this journal
The newest in Journal of Biomedical Science & Applications.
Commentary · 28 Jan 2025
Biomedical Science Contributions to Precision and Personalized Medicine
Opinion · 28 Jan 2025
Biomedical Imaging Innovations for Translational Medical Applications
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biomedical Science & Applications
- BylineArticles whose byline prints “David Tolfree”
